The GOLD International COPD Conference will cover underdiagnosis, exacerbations, mucus, biologics, and a preview of the 2027 GOLD Report.
Commentary|Podcasts|August 31, 2023
Managed Care Cast Presents: Stakeholders Summit—Biosimilars in Inflammatory Diseases, Part 1
Author(s)Laura Joszt, MA
In part 1 of this 2-part podcast, a panel of experts discusses the clinical manifestations of inflammatory diseases and the potential for biosimilars to treat these diseases.
Advertisement
Today we are bringing you part 1 of a 2-part sponsored podcast series discussing the use of biosimilars in inflammatory diseases. The discussion was moderated by Ryan Haumschild, PharmD, director of Pharmacy Services at Emory Healthcare and Winship Cancer Institute.
The conversation for today’s podcast includes the clinical manifestation of inflammatory diseases, comorbid conditions, and the role of biologics and biosimilars in disease management.
Advertisement
Related to this article
People with multiple sclerosis make up most of a survey linking variable-friction footwear to fewer self-reported falls.
Clinicians at an AJMC roundtable in Cleveland said Medicare's GLP-1 Bridge came late and that cost and capacity gaps persist.
Nathan Estrada, DPT, explains which patients, including those with multiple sclerosis, may benefit from footwear that adapts to gait.
Patients with Sjögren disease have 5-fold higher odds of depression, yet screening tools remain unvalidated, a new review finds.
Medicare Advantage exits, rising ACA premiums, a Medicare for America bill, and a Medicaid work rule ruling frame health policy on Election Day.
Patient selection raised detection of pathogenic germline variants from 6% to 27% in lung cancer studies.
Pharmacists outline new oncologic therapeutics, from pancreatic cancer to myeloma, and what high prices and crowded markets mean for payers.
Advertisement
Advertisement
Trending on AJMC
1
First-Line Vitiligo Treatment: Topical JAK Inhibitors and Phototherapy
2
Unanswered Questions in First- and Second-Line mCRC Care
3
Planning for Third-Line Therapy and Treatment Rechallenge in mCRC
4
Multidisciplinary Care for Vitiligo: Beyond Dermatology
5